Videos
David J. Straus, MD, discusses the toxicities associated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with stage III/IV classical Hodgkin lymphoma, according to data from the 3-year update of the ECHELON-1 trial presented at the 2019 ASCO Annual Meeting.
David Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, discussed with <em>Targeted Oncology</em>at the 2019 ASCO Annual Meeting how the Association of Community Cancer Centers (ACCC) is the change agent for helping physicians provide their patients with quality care. <br />
Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab plus erlotinib was compared to erlotinib plus placebo in patients with EGFR-mutated non–small cell lung cancer. These data were presented at the 2019 ASCO Annual Meeting.
Jorge E. Cortes, MD, discusses the results from the ENESTFreedom study, which evaluated the use of nilotinib as a treatment for patients with BCR-ABL1–positive chronic myeloid leukemia in the chronic phase.<br />
Josep M. Llovet, MD, PhD, discusses the evolution of treatment options for patients with hepatocellular carcinoma.
Andrew L. Pecora, MD, FACP, CPE, discusses the biggest areas of research in the field of multiple myeloma. Pecora says that there has been a surprising number of advances in the field, with current research mostly focused on 1 of 3 areas.
